SlideShare a Scribd company logo
1 of 23
Download to read offline
www.ngsmips.nitte.edu.in
CTD
Common Technical Document
Department of Regulatory Affairs
NGSMIPS, Nitte University
Mangalore
- Swapnil Dylan Fernandes
1st M.Pharm
1
www.ngsmips.nitte.edu.in
WILL DISCUSS ABOUT :-
 What is CTD?
 Why CTD?
 Preparing and organizing the CTD (Modules)
 Conclusion
 References
2
www.ngsmips.nitte.edu.in
ABBREVIATIONS
 CDSCO: Central Drugs Standard Control Organization
 CTD: Common Technical Document
 DCGI: Drug Controller General of India
 eCTD: Electronic Common Technical Document
 FDA: Food and Drug Administration
 ICH: International Conference on Harmonisation
 IND: Investigational New Drug application
 NDA: New Drug Application
 USFDA: US Food and Drug Administration
 TGA: Therapeutic Goods Administration
 EMA: European Medicines Agency
3
www.ngsmips.nitte.edu.in
WHAT IS CTD?
 Application format
 CTD IS A JOINT EFFORT OF 3 REGULATORY AGENCIES:
 1.European Medicines Agency (EMEA, Europe),
 2.Food and Drug Administration (FDA, USA) and
 3.Ministry of Health, Labour and Welfare (MHLW,Japan).
 The CTD is a set of specifications for a dossier for the
registration of medicines (TGA)
 CTD is an internationally agreed “well structured common
format” for the organization of the technical requirements
that is to be submitted to the regulatory authority as an
application for the registration of pharmaceuticals for human
use in all three ICH regions (U.S.A., Europe and Japan).
4
www.ngsmips.nitte.edu.in
WHY CTD?
 Hurdles put down by the 3 major regulatory
authorities.
 Objective of ICH to prepare the CTD.
 Reduce the time and resources used to compile
applications
 It will ease the preparation of electronic submissions.
 To facilitate simultaneous submission in three
regions.
 To facilitate easier exchange of regulatory
information and thereby ensure faster availability of
new medicines.
5
www.ngsmips.nitte.edu.in
MODULES OF CTD
 It is organized into:-
 Module 1: General Information
 Module 2: CTD summaries
 Module 3: Quality
 Module 4: Nonclinical study reports
 Module 5: Clinical study reports
6
www.ngsmips.nitte.edu.in 7
www.ngsmips.nitte.edu.in
MODULE 1
 Administrative information and prescribing
information.
 Document specific to each region.
 E.g. Application form
Proposed label for use in the region
8
www.ngsmips.nitte.edu.in
MODULE 1: GENERAL INFORMATION
1.1. Covering letter & comprehensive table of contents
1.2. Administrative information
 Brief introduction about the applicant company
 Duly filled and signed application in Form 44 and Treasury Challan
 Legal and Critical Documents such as Copy of Clinical Trial/BE., No
Objection letters issued by CDSCO, Batch release certificate issued by
National Regulatory Authorities
E.g. For manufacture and marketing of finished products, in addition to the above
mentioned docs,
Copy of existing manufacturing license in Form 25 / 28.
Copy of Form-29
Certificate of Analysis
Coordinates related to the application
9
www.ngsmips.nitte.edu.in
1.3 General Information on Drug Product
1.5 Regulatory status in other countries
1.6 Domestic price of the drug followed in the countries of
1.7 A brief profile of the manufacturer’s research activity
1.8 A brief profile of the manufacturer’s business activity in
domestic as well as global market
1.9 Information regarding involvement of experts, if any
1.10 Samples of drug product
1.11 Promotional materials
10
www.ngsmips.nitte.edu.in
MODULE 2 - CTD SUMMARIES
2.1 Table of content of module 2
2.2 Introduction
2.3 Quality overall summaries
2.4 Non-clinical overview
2.5 Clinical overview
2.6 Non-clinical summaries
2.7 Clinical summaries
11
www.ngsmips.nitte.edu.in
 2.3 QUALITY OVERALL SUMMARIES
– The Quality Overall Summary (QOS) is an outline of
data presented in Module 3.
– Entire information present in Module 3
corresponding sections is not provided, but, provide
brief information picked from relevant sections.
– 2.3.S Summary Of Drug Substance
– 2.3.P Summary Of Drug Product
12
www.ngsmips.nitte.edu.in
 2.4 NON-CLINICAL OVERVIEW
– 2.4.1 Introduction and GLP statement
– 2.4.2 Overview of the Non Clinical Testing Strategy
– 2.4.3 Pharmacology
– 2.4.4 Pharmacokinetics
– 2.4.5 Toxicology
– 2.4.6 Integrated Overview and Conclusions
– 2.4.7 List of Literature References
 Implications of nonclinical findings for the safe use of
the pharmaceutical.
13
www.ngsmips.nitte.edu.in
 2.5 CLINICAL OVERVIEW
– Overview of analysis of the clinical data
– Provide a brief overview of the clinical findings
– Analyse the benefits and risks of the medicinal product in its
intended use
• 2.5.1 Product Development Rationale
• 2.5.2 Overview of Biopharmaceutics
• 2.5.3. Overview of Clinical Pharmacology
• 2.5.4 Overview of Efficacy
• 2.5.5 Overview of Safety
• 2.5.6 Benefits and Risks Conclusions
• 2.5.7 Literature References
14
www.ngsmips.nitte.edu.in
 2.6 NON-CLINICAL SUMMARIES
– Summary of pharmacokinetic, pharmacological
and toxicology studies – in-vivo/in-vitro, species,
route and duration
– Appropriate age and gender related effects
15
www.ngsmips.nitte.edu.in
 2.7 CLINICAL SUMMARIES
– This section is intended to provide a detailed, factual
summarization of all of the clinical information in the
CTD. This includes:
• information provided in clinical study reports
• information obtained from any analyses for which full
reports have been included in Module 5; and
• post-marketing data for products that have been marketed
in other regions
– Synopses of Individual Studies
16
www.ngsmips.nitte.edu.in
MODULE 3 - QUALITY
 The Quality section of the Common Technical Document (M4Q)
provides a harmonised structure and format for presenting CMC
(Chemistry, Manufacturing and Controls) information in a
registration dossier.
17
Module 3 content
Module Content
3.1 Module 3 table of contents
3.2 Body of data
3.3 Literature references
www.ngsmips.nitte.edu.in
 3.2 BODY OF DATA
– 3.2.S DRUG SUBSTANCE(S)
 3.2.S.1 General information (name, manufacturer)
 3.2.S.2 Manufacture of Drug Substance (name, manufacturer)
• 3.2.S.3 Characterization of Drug Substance
• 3.2.S.4 Quality control of Drug Substance
• 3.2.S.5 Reference Standards or Materials
• 3.2.S.6 Container Closure System
• 3.2.S.7 Stability of Drug Substance
– 3.2.P DRUG PRODUCT (NAME, DOSAGE FORM)
 3.2.P.4 Control of Excipients
 3.2.P.5 Control of Drug Product
18
www.ngsmips.nitte.edu.in
MODULE 4: NON-CLINICAL STUDY REPORTS
 Module 4 describes the format and organisation
of the nonclinical (pharmaco-toxicological) data
relevant to the application.
– 4.2 STUDY REPORTS
– 4.2.1 Pharmacology
– 4.2.2 Pharmacokinetics
– 4.2.3 Toxicology
– 4.3 literature references
19
www.ngsmips.nitte.edu.in
MODULE 5: CLINICAL STUDY REPORTS
 Module 5 describes the format and organisation of the clinical data
relevant to the application.
– 5.3.1 Reports of Biopharmaceutical Studies
– 5.3.2 Reports of Studies Pertinent to Pharmacokinetics Using
Human Biomaterials
– 5.3.3 Reports of Human Pharmacokinetic (PK) Studies
– 5.3.4 Reports of Human Pharmacodynamic (PD) Studies
– 5.3.5 Reports of Efficacy and Safety Studies
– 5.3.6 Reports of Post-Marketing Experience
– 5.3.7 Case Report Forms and Individual Patient Listings
– 5.4 literature references
20
www.ngsmips.nitte.edu.in 21
GUIDANCE FOR THE INDUSTRY
 Divided in 4 guidance document
www.ngsmips.nitte.edu.in
CONCLUSION
 Whilst the realization of the CTD took many years,
there is now a common format for the submission of
Marketing Authorizations Applications across the
three ICH regions - Europe, Japan and the USA.
 This should facilitate pharmaceutical companies to
make simultaneous filings in the ICH regions as it will
eliminate the extensive work previously required to
convert, for example, a US dossier to an EU dossier
and vice versa.
22
www.ngsmips.nitte.edu.in
REFERENCES
1. “Guidance for Industry on Preparation of Common Technical Document
for Import / Manufacture And Marketing Approval Of New Drugs For
Human Use (New Drug Application – NDA)”. Available at
http://cdsco.nic.in/CTD_Guidance%20-Final.pdf
2. “Guideline M4: The Common Technical Document”. Available at
http://www.ich.org/products/ctd.html
3. “ICH Harmonised Tripartite Guideline: Organisation Of The Common
Technical Document For The Registration Of Pharmaceuticals For Human
Use M4”. Available at http://www.ich.org/fileadmin
23

More Related Content

What's hot

5. Unit-V- Regulatory Concepts.
5. Unit-V- Regulatory Concepts.5. Unit-V- Regulatory Concepts.
5. Unit-V- Regulatory Concepts.Audumbar Mali
 
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCT
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCTCopp - CERTIFICATE OF PHARMACEUTICAL PRODUCT
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCTSuraj Pamadi
 
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product developmentSachin G
 
NDA and ANDA regulatory approval process
NDA and ANDA regulatory approval processNDA and ANDA regulatory approval process
NDA and ANDA regulatory approval processNilesh Gawade
 
Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]Sagar Savale
 
Regulatory requirements for drug approval
Regulatory requirements for drug approval Regulatory requirements for drug approval
Regulatory requirements for drug approval Namdeo Shinde
 
Hatch waxman act & amendments ppt
Hatch waxman act & amendments  pptHatch waxman act & amendments  ppt
Hatch waxman act & amendments pptAlexa Jacob
 
Clinical trail protocol and development
Clinical trail protocol and developmentClinical trail protocol and development
Clinical trail protocol and developmentChintamBaladattaSai
 
2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.Audumbar Mali
 
Investigational New drug application [INDA]
Investigational New drug application [INDA]Investigational New drug application [INDA]
Investigational New drug application [INDA]Sagar Savale
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...Audumbar Mali
 
ICH: Introduction, objectives & guidelines: A brief insight.
ICH: Introduction, objectives & guidelines: A brief insight.ICH: Introduction, objectives & guidelines: A brief insight.
ICH: Introduction, objectives & guidelines: A brief insight.RxVichuZ
 
DMF Drug Master File
DMF   Drug Master FileDMF   Drug Master File
DMF Drug Master FileRushi Mendhe
 

What's hot (20)

5. Unit-V- Regulatory Concepts.
5. Unit-V- Regulatory Concepts.5. Unit-V- Regulatory Concepts.
5. Unit-V- Regulatory Concepts.
 
Code of Federal Regulations
Code of Federal RegulationsCode of Federal Regulations
Code of Federal Regulations
 
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCT
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCTCopp - CERTIFICATE OF PHARMACEUTICAL PRODUCT
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCT
 
CTD and eCTD
CTD and eCTDCTD and eCTD
CTD and eCTD
 
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product development
 
NDA and ANDA regulatory approval process
NDA and ANDA regulatory approval processNDA and ANDA regulatory approval process
NDA and ANDA regulatory approval process
 
Orange book
Orange bookOrange book
Orange book
 
Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]Abbreviated New Drug Application [ANDA]
Abbreviated New Drug Application [ANDA]
 
The introduction of an orange book
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange book
 
DMF -Drug Master File
DMF -Drug Master File DMF -Drug Master File
DMF -Drug Master File
 
New drug approval
New drug approvalNew drug approval
New drug approval
 
Supac
SupacSupac
Supac
 
Regulatory requirements for drug approval
Regulatory requirements for drug approval Regulatory requirements for drug approval
Regulatory requirements for drug approval
 
Hatch waxman act & amendments ppt
Hatch waxman act & amendments  pptHatch waxman act & amendments  ppt
Hatch waxman act & amendments ppt
 
Clinical trail protocol and development
Clinical trail protocol and developmentClinical trail protocol and development
Clinical trail protocol and development
 
2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.
 
Investigational New drug application [INDA]
Investigational New drug application [INDA]Investigational New drug application [INDA]
Investigational New drug application [INDA]
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
 
ICH: Introduction, objectives & guidelines: A brief insight.
ICH: Introduction, objectives & guidelines: A brief insight.ICH: Introduction, objectives & guidelines: A brief insight.
ICH: Introduction, objectives & guidelines: A brief insight.
 
DMF Drug Master File
DMF   Drug Master FileDMF   Drug Master File
DMF Drug Master File
 

Similar to Common Technical Document (CTD)

Content and format of dossier filling in india
Content and format of dossier filling in india Content and format of dossier filling in india
Content and format of dossier filling in india sandeep bansal
 
IND Data Requirements and US FDA Submission Process.pdf
IND Data Requirements and US FDA Submission Process.pdfIND Data Requirements and US FDA Submission Process.pdf
IND Data Requirements and US FDA Submission Process.pdfProRelixInfo
 
IND Data Requirements and US FDA Submission.pdf
IND Data Requirements and US FDA Submission.pdfIND Data Requirements and US FDA Submission.pdf
IND Data Requirements and US FDA Submission.pdfTrishalaDeshmane
 
2103313001_dhavalkumar H Rathod_MPH104.pptx
2103313001_dhavalkumar H Rathod_MPH104.pptx2103313001_dhavalkumar H Rathod_MPH104.pptx
2103313001_dhavalkumar H Rathod_MPH104.pptxMariyambibiMandarawa1
 
cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]Akshay Patil
 
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1    productregistrationanddrugapprovalprocessinus.pptakshay regulatory seminar 1    productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.pptGaneshSureshKumbhar
 
common technical document vs electronic common technical document
common technical document vs electronic common technical document common technical document vs electronic common technical document
common technical document vs electronic common technical document MayankGupta851
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)Tanmay Madhavi
 
Common technical document
Common technical document Common technical document
Common technical document Aqsa Tufail
 
Guidance for industry content and format of investigational new drug applicat...
Guidance for industry content and format of investigational new drug applicat...Guidance for industry content and format of investigational new drug applicat...
Guidance for industry content and format of investigational new drug applicat...Suraj Pamadi
 
Investigational medicinal product dossier
Investigational medicinal product dossierInvestigational medicinal product dossier
Investigational medicinal product dossierMayuriGhavate
 
Fundamental concept of regulatory affairs in pharmaceutical & biotechnology
Fundamental concept of regulatory affairs in pharmaceutical & biotechnologyFundamental concept of regulatory affairs in pharmaceutical & biotechnology
Fundamental concept of regulatory affairs in pharmaceutical & biotechnologyHitendra Singh
 
Regulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDRegulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDMahesh shinde
 
New drug application
New drug applicationNew drug application
New drug applicationnishuyadav17
 
Regulatory affairs and Intellectual Property Rights
Regulatory affairs and Intellectual Property RightsRegulatory affairs and Intellectual Property Rights
Regulatory affairs and Intellectual Property Rightssantoshnarla
 
Investigation of medicinal product dossier
Investigation of medicinal product dossierInvestigation of medicinal product dossier
Investigation of medicinal product dossierDeeptiGupta154
 

Similar to Common Technical Document (CTD) (20)

Content and format of dossier filling in india
Content and format of dossier filling in india Content and format of dossier filling in india
Content and format of dossier filling in india
 
NDA.pptx
NDA.pptxNDA.pptx
NDA.pptx
 
NDA.pptx
NDA.pptxNDA.pptx
NDA.pptx
 
IND Data Requirements and US FDA Submission Process.pdf
IND Data Requirements and US FDA Submission Process.pdfIND Data Requirements and US FDA Submission Process.pdf
IND Data Requirements and US FDA Submission Process.pdf
 
IND Data Requirements and US FDA Submission.pdf
IND Data Requirements and US FDA Submission.pdfIND Data Requirements and US FDA Submission.pdf
IND Data Requirements and US FDA Submission.pdf
 
Ctd and e ctd
Ctd and e ctdCtd and e ctd
Ctd and e ctd
 
Drug Regulatory affairs
Drug Regulatory affairsDrug Regulatory affairs
Drug Regulatory affairs
 
2103313001_dhavalkumar H Rathod_MPH104.pptx
2103313001_dhavalkumar H Rathod_MPH104.pptx2103313001_dhavalkumar H Rathod_MPH104.pptx
2103313001_dhavalkumar H Rathod_MPH104.pptx
 
cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]
 
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1    productregistrationanddrugapprovalprocessinus.pptakshay regulatory seminar 1    productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
 
common technical document vs electronic common technical document
common technical document vs electronic common technical document common technical document vs electronic common technical document
common technical document vs electronic common technical document
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)
 
Common technical document
Common technical document Common technical document
Common technical document
 
Guidance for industry content and format of investigational new drug applicat...
Guidance for industry content and format of investigational new drug applicat...Guidance for industry content and format of investigational new drug applicat...
Guidance for industry content and format of investigational new drug applicat...
 
Investigational medicinal product dossier
Investigational medicinal product dossierInvestigational medicinal product dossier
Investigational medicinal product dossier
 
Fundamental concept of regulatory affairs in pharmaceutical & biotechnology
Fundamental concept of regulatory affairs in pharmaceutical & biotechnologyFundamental concept of regulatory affairs in pharmaceutical & biotechnology
Fundamental concept of regulatory affairs in pharmaceutical & biotechnology
 
Regulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDRegulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTD
 
New drug application
New drug applicationNew drug application
New drug application
 
Regulatory affairs and Intellectual Property Rights
Regulatory affairs and Intellectual Property RightsRegulatory affairs and Intellectual Property Rights
Regulatory affairs and Intellectual Property Rights
 
Investigation of medicinal product dossier
Investigation of medicinal product dossierInvestigation of medicinal product dossier
Investigation of medicinal product dossier
 

More from Swapnil Fernandes

MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...Swapnil Fernandes
 
FSSAI REGULATIONS FOR THE IMPORT, MANUFACTURE AND SALE OF NUTRACEUTICALS IN I...
FSSAI REGULATIONS FOR THE IMPORT, MANUFACTURE AND SALE OF NUTRACEUTICALS IN I...FSSAI REGULATIONS FOR THE IMPORT, MANUFACTURE AND SALE OF NUTRACEUTICALS IN I...
FSSAI REGULATIONS FOR THE IMPORT, MANUFACTURE AND SALE OF NUTRACEUTICALS IN I...Swapnil Fernandes
 
Current Good Manufacturing Practices
Current Good Manufacturing PracticesCurrent Good Manufacturing Practices
Current Good Manufacturing PracticesSwapnil Fernandes
 
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...Swapnil Fernandes
 
Good Automated Laboratory Practices
Good Automated Laboratory PracticesGood Automated Laboratory Practices
Good Automated Laboratory PracticesSwapnil Fernandes
 

More from Swapnil Fernandes (6)

MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
 
FSSAI REGULATIONS FOR THE IMPORT, MANUFACTURE AND SALE OF NUTRACEUTICALS IN I...
FSSAI REGULATIONS FOR THE IMPORT, MANUFACTURE AND SALE OF NUTRACEUTICALS IN I...FSSAI REGULATIONS FOR THE IMPORT, MANUFACTURE AND SALE OF NUTRACEUTICALS IN I...
FSSAI REGULATIONS FOR THE IMPORT, MANUFACTURE AND SALE OF NUTRACEUTICALS IN I...
 
Current Good Manufacturing Practices
Current Good Manufacturing PracticesCurrent Good Manufacturing Practices
Current Good Manufacturing Practices
 
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...
 
The Pharmacy act, 1948
The Pharmacy act, 1948The Pharmacy act, 1948
The Pharmacy act, 1948
 
Good Automated Laboratory Practices
Good Automated Laboratory PracticesGood Automated Laboratory Practices
Good Automated Laboratory Practices
 

Recently uploaded

DISASTER MANAGE-WPS Office-1.pptx PREPARED BY NEHA KEWAT
DISASTER MANAGE-WPS Office-1.pptx PREPARED BY NEHA KEWATDISASTER MANAGE-WPS Office-1.pptx PREPARED BY NEHA KEWAT
DISASTER MANAGE-WPS Office-1.pptx PREPARED BY NEHA KEWATNehaKewat
 
Enhancing Health Through Personalized Nutrition
Enhancing Health Through Personalized NutritionEnhancing Health Through Personalized Nutrition
Enhancing Health Through Personalized NutritionNeighborhood Trainer
 
arpita 1-1.pptx management of nursing service and education
arpita 1-1.pptx management of nursing service and educationarpita 1-1.pptx management of nursing service and education
arpita 1-1.pptx management of nursing service and educationNursing education
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Oleg Kshivets
 
Unlocking the Mysteries of the Lymphatic System
Unlocking the Mysteries of the Lymphatic SystemUnlocking the Mysteries of the Lymphatic System
Unlocking the Mysteries of the Lymphatic SystemSasikiranMarri
 
Understanding Cholera: Epidemiology, Prevention, and Control.pdf
Understanding Cholera: Epidemiology, Prevention, and Control.pdfUnderstanding Cholera: Epidemiology, Prevention, and Control.pdf
Understanding Cholera: Epidemiology, Prevention, and Control.pdfSasikiranMarri
 
2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...
2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...
2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...Compliatric Where Compliance Happens
 
Test bank criminal behavior a psychological approach 12e bartol.pdf
Test bank criminal behavior a psychological approach 12e bartol.pdfTest bank criminal behavior a psychological approach 12e bartol.pdf
Test bank criminal behavior a psychological approach 12e bartol.pdfmarcuskenyatta275
 
The Best Diet for Preventing and Managing Kidney Stones .pptx
The Best Diet for Preventing and Managing Kidney Stones .pptxThe Best Diet for Preventing and Managing Kidney Stones .pptx
The Best Diet for Preventing and Managing Kidney Stones .pptxBarshaBarsha6
 
CASE STUDY ON CHRONIC KIDNEY DISEASE.pptx
CASE  STUDY ON CHRONIC KIDNEY DISEASE.pptxCASE  STUDY ON CHRONIC KIDNEY DISEASE.pptx
CASE STUDY ON CHRONIC KIDNEY DISEASE.pptxdrsriram2001
 
preeti cornea ..physiology of cornea.ppt
preeti cornea ..physiology of cornea.pptpreeti cornea ..physiology of cornea.ppt
preeti cornea ..physiology of cornea.pptpreetiagarwal53
 
Presentation for Alzheimers Disease.pptx
Presentation for Alzheimers Disease.pptxPresentation for Alzheimers Disease.pptx
Presentation for Alzheimers Disease.pptxravisutar1
 
Discover the Art Deco Style at Spa Dental
Discover the Art Deco Style at Spa DentalDiscover the Art Deco Style at Spa Dental
Discover the Art Deco Style at Spa DentalA-dec Australia
 
2024 Medicare AEP Shopping Experience: Consumer Insight Survey
2024 Medicare AEP Shopping Experience: Consumer Insight Survey2024 Medicare AEP Shopping Experience: Consumer Insight Survey
2024 Medicare AEP Shopping Experience: Consumer Insight SurveyMedia Logic
 
Weighing the Risks and Benefits: Angioplasty at Gokuldas Hospitals
Weighing the Risks and Benefits: Angioplasty at Gokuldas HospitalsWeighing the Risks and Benefits: Angioplasty at Gokuldas Hospitals
Weighing the Risks and Benefits: Angioplasty at Gokuldas HospitalsGokuldas Hospital
 
The goal of a Code Review Security Aardwolf Security.docx
The goal of a Code Review Security Aardwolf Security.docxThe goal of a Code Review Security Aardwolf Security.docx
The goal of a Code Review Security Aardwolf Security.docxAardwolf Security
 
COP NCM 122. Intensive nursing practicum course outline presentation pptx
COP NCM 122. Intensive nursing practicum course outline presentation pptxCOP NCM 122. Intensive nursing practicum course outline presentation pptx
COP NCM 122. Intensive nursing practicum course outline presentation pptxCarolyn Calupitan
 
Elevating Fitness & Well-being with Neighborhood Trainers.
Elevating Fitness & Well-being with Neighborhood Trainers.Elevating Fitness & Well-being with Neighborhood Trainers.
Elevating Fitness & Well-being with Neighborhood Trainers.Neighborhood Trainer
 
Emergency ambulance portal-PPT-3g2pqy.pptx
Emergency ambulance portal-PPT-3g2pqy.pptxEmergency ambulance portal-PPT-3g2pqy.pptx
Emergency ambulance portal-PPT-3g2pqy.pptxdragonaklevel7
 

Recently uploaded (20)

Sarah A Reed: A Rennaissance Women her spirit lives one 153 Years Later
Sarah A Reed: A Rennaissance Women her spirit lives one 153 Years LaterSarah A Reed: A Rennaissance Women her spirit lives one 153 Years Later
Sarah A Reed: A Rennaissance Women her spirit lives one 153 Years Later
 
DISASTER MANAGE-WPS Office-1.pptx PREPARED BY NEHA KEWAT
DISASTER MANAGE-WPS Office-1.pptx PREPARED BY NEHA KEWATDISASTER MANAGE-WPS Office-1.pptx PREPARED BY NEHA KEWAT
DISASTER MANAGE-WPS Office-1.pptx PREPARED BY NEHA KEWAT
 
Enhancing Health Through Personalized Nutrition
Enhancing Health Through Personalized NutritionEnhancing Health Through Personalized Nutrition
Enhancing Health Through Personalized Nutrition
 
arpita 1-1.pptx management of nursing service and education
arpita 1-1.pptx management of nursing service and educationarpita 1-1.pptx management of nursing service and education
arpita 1-1.pptx management of nursing service and education
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
 
Unlocking the Mysteries of the Lymphatic System
Unlocking the Mysteries of the Lymphatic SystemUnlocking the Mysteries of the Lymphatic System
Unlocking the Mysteries of the Lymphatic System
 
Understanding Cholera: Epidemiology, Prevention, and Control.pdf
Understanding Cholera: Epidemiology, Prevention, and Control.pdfUnderstanding Cholera: Epidemiology, Prevention, and Control.pdf
Understanding Cholera: Epidemiology, Prevention, and Control.pdf
 
2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...
2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...
2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...
 
Test bank criminal behavior a psychological approach 12e bartol.pdf
Test bank criminal behavior a psychological approach 12e bartol.pdfTest bank criminal behavior a psychological approach 12e bartol.pdf
Test bank criminal behavior a psychological approach 12e bartol.pdf
 
The Best Diet for Preventing and Managing Kidney Stones .pptx
The Best Diet for Preventing and Managing Kidney Stones .pptxThe Best Diet for Preventing and Managing Kidney Stones .pptx
The Best Diet for Preventing and Managing Kidney Stones .pptx
 
CASE STUDY ON CHRONIC KIDNEY DISEASE.pptx
CASE  STUDY ON CHRONIC KIDNEY DISEASE.pptxCASE  STUDY ON CHRONIC KIDNEY DISEASE.pptx
CASE STUDY ON CHRONIC KIDNEY DISEASE.pptx
 
preeti cornea ..physiology of cornea.ppt
preeti cornea ..physiology of cornea.pptpreeti cornea ..physiology of cornea.ppt
preeti cornea ..physiology of cornea.ppt
 
Presentation for Alzheimers Disease.pptx
Presentation for Alzheimers Disease.pptxPresentation for Alzheimers Disease.pptx
Presentation for Alzheimers Disease.pptx
 
Discover the Art Deco Style at Spa Dental
Discover the Art Deco Style at Spa DentalDiscover the Art Deco Style at Spa Dental
Discover the Art Deco Style at Spa Dental
 
2024 Medicare AEP Shopping Experience: Consumer Insight Survey
2024 Medicare AEP Shopping Experience: Consumer Insight Survey2024 Medicare AEP Shopping Experience: Consumer Insight Survey
2024 Medicare AEP Shopping Experience: Consumer Insight Survey
 
Weighing the Risks and Benefits: Angioplasty at Gokuldas Hospitals
Weighing the Risks and Benefits: Angioplasty at Gokuldas HospitalsWeighing the Risks and Benefits: Angioplasty at Gokuldas Hospitals
Weighing the Risks and Benefits: Angioplasty at Gokuldas Hospitals
 
The goal of a Code Review Security Aardwolf Security.docx
The goal of a Code Review Security Aardwolf Security.docxThe goal of a Code Review Security Aardwolf Security.docx
The goal of a Code Review Security Aardwolf Security.docx
 
COP NCM 122. Intensive nursing practicum course outline presentation pptx
COP NCM 122. Intensive nursing practicum course outline presentation pptxCOP NCM 122. Intensive nursing practicum course outline presentation pptx
COP NCM 122. Intensive nursing practicum course outline presentation pptx
 
Elevating Fitness & Well-being with Neighborhood Trainers.
Elevating Fitness & Well-being with Neighborhood Trainers.Elevating Fitness & Well-being with Neighborhood Trainers.
Elevating Fitness & Well-being with Neighborhood Trainers.
 
Emergency ambulance portal-PPT-3g2pqy.pptx
Emergency ambulance portal-PPT-3g2pqy.pptxEmergency ambulance portal-PPT-3g2pqy.pptx
Emergency ambulance portal-PPT-3g2pqy.pptx
 

Common Technical Document (CTD)

  • 1. www.ngsmips.nitte.edu.in CTD Common Technical Document Department of Regulatory Affairs NGSMIPS, Nitte University Mangalore - Swapnil Dylan Fernandes 1st M.Pharm 1
  • 2. www.ngsmips.nitte.edu.in WILL DISCUSS ABOUT :-  What is CTD?  Why CTD?  Preparing and organizing the CTD (Modules)  Conclusion  References 2
  • 3. www.ngsmips.nitte.edu.in ABBREVIATIONS  CDSCO: Central Drugs Standard Control Organization  CTD: Common Technical Document  DCGI: Drug Controller General of India  eCTD: Electronic Common Technical Document  FDA: Food and Drug Administration  ICH: International Conference on Harmonisation  IND: Investigational New Drug application  NDA: New Drug Application  USFDA: US Food and Drug Administration  TGA: Therapeutic Goods Administration  EMA: European Medicines Agency 3
  • 4. www.ngsmips.nitte.edu.in WHAT IS CTD?  Application format  CTD IS A JOINT EFFORT OF 3 REGULATORY AGENCIES:  1.European Medicines Agency (EMEA, Europe),  2.Food and Drug Administration (FDA, USA) and  3.Ministry of Health, Labour and Welfare (MHLW,Japan).  The CTD is a set of specifications for a dossier for the registration of medicines (TGA)  CTD is an internationally agreed “well structured common format” for the organization of the technical requirements that is to be submitted to the regulatory authority as an application for the registration of pharmaceuticals for human use in all three ICH regions (U.S.A., Europe and Japan). 4
  • 5. www.ngsmips.nitte.edu.in WHY CTD?  Hurdles put down by the 3 major regulatory authorities.  Objective of ICH to prepare the CTD.  Reduce the time and resources used to compile applications  It will ease the preparation of electronic submissions.  To facilitate simultaneous submission in three regions.  To facilitate easier exchange of regulatory information and thereby ensure faster availability of new medicines. 5
  • 6. www.ngsmips.nitte.edu.in MODULES OF CTD  It is organized into:-  Module 1: General Information  Module 2: CTD summaries  Module 3: Quality  Module 4: Nonclinical study reports  Module 5: Clinical study reports 6
  • 8. www.ngsmips.nitte.edu.in MODULE 1  Administrative information and prescribing information.  Document specific to each region.  E.g. Application form Proposed label for use in the region 8
  • 9. www.ngsmips.nitte.edu.in MODULE 1: GENERAL INFORMATION 1.1. Covering letter & comprehensive table of contents 1.2. Administrative information  Brief introduction about the applicant company  Duly filled and signed application in Form 44 and Treasury Challan  Legal and Critical Documents such as Copy of Clinical Trial/BE., No Objection letters issued by CDSCO, Batch release certificate issued by National Regulatory Authorities E.g. For manufacture and marketing of finished products, in addition to the above mentioned docs, Copy of existing manufacturing license in Form 25 / 28. Copy of Form-29 Certificate of Analysis Coordinates related to the application 9
  • 10. www.ngsmips.nitte.edu.in 1.3 General Information on Drug Product 1.5 Regulatory status in other countries 1.6 Domestic price of the drug followed in the countries of 1.7 A brief profile of the manufacturer’s research activity 1.8 A brief profile of the manufacturer’s business activity in domestic as well as global market 1.9 Information regarding involvement of experts, if any 1.10 Samples of drug product 1.11 Promotional materials 10
  • 11. www.ngsmips.nitte.edu.in MODULE 2 - CTD SUMMARIES 2.1 Table of content of module 2 2.2 Introduction 2.3 Quality overall summaries 2.4 Non-clinical overview 2.5 Clinical overview 2.6 Non-clinical summaries 2.7 Clinical summaries 11
  • 12. www.ngsmips.nitte.edu.in  2.3 QUALITY OVERALL SUMMARIES – The Quality Overall Summary (QOS) is an outline of data presented in Module 3. – Entire information present in Module 3 corresponding sections is not provided, but, provide brief information picked from relevant sections. – 2.3.S Summary Of Drug Substance – 2.3.P Summary Of Drug Product 12
  • 13. www.ngsmips.nitte.edu.in  2.4 NON-CLINICAL OVERVIEW – 2.4.1 Introduction and GLP statement – 2.4.2 Overview of the Non Clinical Testing Strategy – 2.4.3 Pharmacology – 2.4.4 Pharmacokinetics – 2.4.5 Toxicology – 2.4.6 Integrated Overview and Conclusions – 2.4.7 List of Literature References  Implications of nonclinical findings for the safe use of the pharmaceutical. 13
  • 14. www.ngsmips.nitte.edu.in  2.5 CLINICAL OVERVIEW – Overview of analysis of the clinical data – Provide a brief overview of the clinical findings – Analyse the benefits and risks of the medicinal product in its intended use • 2.5.1 Product Development Rationale • 2.5.2 Overview of Biopharmaceutics • 2.5.3. Overview of Clinical Pharmacology • 2.5.4 Overview of Efficacy • 2.5.5 Overview of Safety • 2.5.6 Benefits and Risks Conclusions • 2.5.7 Literature References 14
  • 15. www.ngsmips.nitte.edu.in  2.6 NON-CLINICAL SUMMARIES – Summary of pharmacokinetic, pharmacological and toxicology studies – in-vivo/in-vitro, species, route and duration – Appropriate age and gender related effects 15
  • 16. www.ngsmips.nitte.edu.in  2.7 CLINICAL SUMMARIES – This section is intended to provide a detailed, factual summarization of all of the clinical information in the CTD. This includes: • information provided in clinical study reports • information obtained from any analyses for which full reports have been included in Module 5; and • post-marketing data for products that have been marketed in other regions – Synopses of Individual Studies 16
  • 17. www.ngsmips.nitte.edu.in MODULE 3 - QUALITY  The Quality section of the Common Technical Document (M4Q) provides a harmonised structure and format for presenting CMC (Chemistry, Manufacturing and Controls) information in a registration dossier. 17 Module 3 content Module Content 3.1 Module 3 table of contents 3.2 Body of data 3.3 Literature references
  • 18. www.ngsmips.nitte.edu.in  3.2 BODY OF DATA – 3.2.S DRUG SUBSTANCE(S)  3.2.S.1 General information (name, manufacturer)  3.2.S.2 Manufacture of Drug Substance (name, manufacturer) • 3.2.S.3 Characterization of Drug Substance • 3.2.S.4 Quality control of Drug Substance • 3.2.S.5 Reference Standards or Materials • 3.2.S.6 Container Closure System • 3.2.S.7 Stability of Drug Substance – 3.2.P DRUG PRODUCT (NAME, DOSAGE FORM)  3.2.P.4 Control of Excipients  3.2.P.5 Control of Drug Product 18
  • 19. www.ngsmips.nitte.edu.in MODULE 4: NON-CLINICAL STUDY REPORTS  Module 4 describes the format and organisation of the nonclinical (pharmaco-toxicological) data relevant to the application. – 4.2 STUDY REPORTS – 4.2.1 Pharmacology – 4.2.2 Pharmacokinetics – 4.2.3 Toxicology – 4.3 literature references 19
  • 20. www.ngsmips.nitte.edu.in MODULE 5: CLINICAL STUDY REPORTS  Module 5 describes the format and organisation of the clinical data relevant to the application. – 5.3.1 Reports of Biopharmaceutical Studies – 5.3.2 Reports of Studies Pertinent to Pharmacokinetics Using Human Biomaterials – 5.3.3 Reports of Human Pharmacokinetic (PK) Studies – 5.3.4 Reports of Human Pharmacodynamic (PD) Studies – 5.3.5 Reports of Efficacy and Safety Studies – 5.3.6 Reports of Post-Marketing Experience – 5.3.7 Case Report Forms and Individual Patient Listings – 5.4 literature references 20
  • 21. www.ngsmips.nitte.edu.in 21 GUIDANCE FOR THE INDUSTRY  Divided in 4 guidance document
  • 22. www.ngsmips.nitte.edu.in CONCLUSION  Whilst the realization of the CTD took many years, there is now a common format for the submission of Marketing Authorizations Applications across the three ICH regions - Europe, Japan and the USA.  This should facilitate pharmaceutical companies to make simultaneous filings in the ICH regions as it will eliminate the extensive work previously required to convert, for example, a US dossier to an EU dossier and vice versa. 22
  • 23. www.ngsmips.nitte.edu.in REFERENCES 1. “Guidance for Industry on Preparation of Common Technical Document for Import / Manufacture And Marketing Approval Of New Drugs For Human Use (New Drug Application – NDA)”. Available at http://cdsco.nic.in/CTD_Guidance%20-Final.pdf 2. “Guideline M4: The Common Technical Document”. Available at http://www.ich.org/products/ctd.html 3. “ICH Harmonised Tripartite Guideline: Organisation Of The Common Technical Document For The Registration Of Pharmaceuticals For Human Use M4”. Available at http://www.ich.org/fileadmin 23